This study is currently not recruiting participants.

Multicenter randomized double-blind parallel-group active controlled superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis (OPTIMUM/AC-058B301 study)

Investigation of Treatments for Relapsing Multiple Sclerosis

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of the study is to compare the efficacy, safety, and tolerability of ponesimod 20 mg vs teriflunomide 14 mg in adult subjects with relapsing forms of Multiple Sclerosis (MS).

Detailed description of study

The purpose of the study is to compare the efficacy, safety, and tolerability of ponesimod 20 mg vs teriflunomide 14 mg in adult subjects with relapsing forms of Multiple Sclerosis (MS).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: multiple sclerosis
  • Age: 100 years or below
  • Gender: All

This study investigates the effectiveness, safety, and tolerability of two treatments for adults with relapsing forms of Multiple Sclerosis (MS). Multiple Sclerosis is a disease where the immune system attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body.

Participants will be assigned to one of two study arms. One group will receive an investigational medication, while the other group will receive a different medication for comparison. The study will monitor health outcomes and any side effects experienced by participants.

  • Who can participate: Adults aged 18 and older with a diagnosis of relapsing forms of Multiple Sclerosis are eligible to participate. Additional eligibility criteria may apply.
  • Study details: Participants will receive either an investigational medication or a comparator medication. Their health outcomes and any side effects will be monitored throughout the study. There is no placebo involved in this study.
Updated on 19 Feb 2024. Study ID: 1502670881

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team